NCT06114511Active, not recruitingPhase 1
A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.1 site in 1 country78 target enrollmentStarted: April 24, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 78
- Locations
- 1
- Primary Endpoint
- Phase Ib: Recommended Phase II Dose (RP2D)
Study Overview
Brief Summary
This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Voluntarily sign the informed consent and follow the requirements of the protocol.
- •No gender limit.
- •Age: ≥18 years old and ≤75 years old.
- •expected survival time ≥3 months.
- •Histologically or cytologically confirmed, unresectable locally advanced or metastatic non-small cell lung cancer.
- •Confirmed known HER2-sensitive mutations, investigator-confirmed previous testing results, and trial site laboratory testing results were acceptable.
- •Patients in the advanced stage who had received platinum-based chemotherapy and immunotherapy concurrent or sequential therapy were unable to tolerate standard treatment or had disease progression during or after treatment.
- •Consent to provide archived tumor tissue or fresh tissue samples from primary or metastatic sites within 2 years for biomarker testing; Participants who were unable to provide tumor tissue samples could be enrolled if they met other inclusion and
Exclusion Criteria
- •after evaluation by investigators.
- •Must have at least one measurable lesion according to RECIST v1.1 definition.
- •ECOG score 0 or
- •Toxicity of previous antineoplastic therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 .
- •No severe cardiac dysfunction, left ventricular ejection fraction ≥50%.
- •Organ function levels must meet the requirements.
- •Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN.
- •Urine protein ≤2+ or ≤1000mg/24h.
- •For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, serum/urine pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.
- •Exclusion Criteria:
- •Received chemotherapy, biological therapy, immunotherapy or other antitumor treatments within 4 weeks or 5 half-lives prior to the first dose (6 weeks for mitomycin and nitrosoureas; oral fluorouracil drugs, etc.).
- •Prior treatment with an ADC drug containing a camptothecin derivative (topoisomerase I inhibitor) as a toxin.
- •Presence of other gene mutations for targeted drug therapy.
- •A history of severe cardiovascular and cerebrovascular diseases.
- •Active autoimmune or inflammatory diseases.
- •Patients with other malignant tumors within 5 years before the first administration.
- •Unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening; Infusion-related thrombosis was excluded.
- •Patients with poorly controlled pericardial effusion, pleural effusion, peritoneal effusion, or pelvic effusion with clinical symptoms were judged by the investigator to be ineligible for enrollment.
- •Hypertension poorly controlled by antihypertensive drugs (systolic BP > 150 mmHg or diastolic blood pressure > 100 mmHg).
- •Current interstitial lung disease, drug-induced interstitial pneumonia, radiation pneumonitis requiring steroid therapy, or a history of these diseases.
- •Patients with central nervous system (CNS) metastases and/or carcinomatous meningitis (meningeal metastases). .
- •Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any ingredient of BL-M07D
- •Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
- •Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number > lower detection limit) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA > lower detection limit).
- •Active infections requiring systemic therapy, such as severe pneumonia, bacteremia, sepsis, etc.
- •Had participated in another clinical trial within 4 weeks before the first dose (calculated from the time of the last dose).
- •Pregnant or lactating women.
- •Other circumstances considered by the investigator to be inappropriate for participation in the trial.
Arms & Interventions
BL-M07D1
Experimental
Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Intervention: BL-M07D1 (Drug)
Outcomes
Primary Outcomes
Phase Ib: Recommended Phase II Dose (RP2D)
Time Frame: Up to 21 days after the first dose
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M07D1.
Phase II: Objective Response Rate (ORR)
Time Frame: Up to approximately 24 months
ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.
Secondary Outcomes
- Cmax(Up to 21 days after the first dose)
- Disease Control Rate (DCR)(Up to approximately 24 months)
- Tmax(Up to 21 days after the first dose)
- Ctrough(Up to 21 days after the first dose)
- Progression-free Survival (PFS)(Up to approximately 24 months)
- Treatment-Emergent Adverse Event (TEAE)(Up to approximately 24 months)
- Phase Ib: Objective Response Rate (ORR)(Up to approximately 24 months)
- Duration of Response (DOR)(Up to approximately 24 months)
- ADA (anti-drug antibody)(Up to approximately 24 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant TumorsAdvanced Malignant TumorsNCT06223841SUNHO（China）BioPharmaceutical CO., Ltd.50
Recruiting
Phase 1
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationNon Small Cell Lung CancerNCT05641493Shanghai Henlius Biotech49
Completed
Phase 1
A Multiple Ascending Dose Trial of CVL-231 in Subjects With SchizophreniaSchizophreniaNCT04136873Cerevel Therapeutics, LLC130
Completed
Phase 1
A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisNCT06281704Akeso34
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaNegative Symptoms in SchizophreniaNCT06107803Minerva Neurosciences17